Position of the Transparency Council – HyQvia (human normal immunoglobulin)
At its meeting on 20 January 2025, the Transparency Council adopted position No. 9/2025 (human normal immunoglobulin) on the evaluation of the drug HyQvia (human normal immunoglobulin) for the indication: under the drug program B.67. “Immunoglobulin treatment of neurological diseases (ICD-10: G61.8, G62.8, G63.1, G70, G04.8, G73.1, G73.2, G72.4, G61.0, G36.0, M33.0, M33.1, M33.2)”.